Effect of Sumatriptan on Levcromakalim-Induced Symptoms in Individuals With Migraine (SLIM)

Effect of Sumatriptan on Levcromakalim-Induced Symptoms in Individuals With Migraine: A Randomized Double-Blind Two-Way Crossover Study

The study aims to explore the effects of Sumatriptan on Levcromakalim-induced migraine in individuals with migraine without aura.

Study Overview

• Status: Completed
• Conditions: Headache; Migraine Without Aura
• Intervention / Treatment: Drug: Levcromakalim; Drug: Sumatriptan; Drug: Saline

Detailed Description

Opening of adenosine triphosphate-sensitive potassium (KATP) channels using Levcromakalim causes migraine attacks with and without aura in a high proportion of patients.

Sumatriptan has been shown to reverse Levcromakalim-induced dilation of the middle meningeal artery and headache in healthy volunteers, indicating that Sumatriptan can overturn the physiological effects of levcromakalim.

The study aims to explore the effects of Sumatriptan on Levcromakalim-induced migraine in individuals with migraine without aura.

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Denmark
  • Zealand
    • Glostrup, Zealand, Denmark, 2600
      • Danish Headache Centre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Participant has provided informed consent prior to initiation of any study-specific activities/procedures.
2. Age ≥18 years upon entry into screening.
3. History of migraine without aura for ≥12 months with a frequency of 1-5 migraine attacks per month before screening according to the International Headache Society (IHS) Classification ICHD-3 (Headache Classification Committee of the International Headache Society, 2018), based on medical records and/or patient self-report.

Exclusion Criteria:

1. History of any primary headache disorder other than migraine without aura, or tension-type headache with a frequency of ≥5 headache days per month before screening according to the International Headache Society (IHS) Classification ICHD-3 (Headache Classification Committee of the International Headache Society, 2018), based on medical records and/or patient self-report.
2. History of any secondary headache disorder before screening according to the International Headache Society (IHS) Classification ICHD-3 (Headache Classification Committee of the International Headache Society, 2018) based on medical records and/or patient self-report.
3. Any headache 48 hours prior to, or any migraine 72 hours prior to the start of the experiment on day 1 and 2.
4. Daily consumption of any drug/medication other than oral contraception (birth control).
5. Intake of prophylactic migraine medication within ≤30 days or 5 plasma half-lives (whichever is longer) prior to screening.
6. The participant is at risk of self-harm or harm to others as evidenced by past suicidal behavior.
7. History or evidence of any other clinically significant disorder, condition, or disease (with the exception of those outlined above) that, in the opinion of the investigator will pose a risk to participant safety or interfere with the study evaluation, procedures or completion.
8. Female participants of childbearing potential with a positive pregnancy test assessed at screening or day 1 by a urine pregnancy test.
9. Female participants who are pregnant or breastfeeding or plan to become pregnant or breastfeed during participation in the study.
10. Evidence of current pregnancy or breastfeeding per participant self-report or medical records.
11. Participants likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the participants' and investigator's knowledge.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Levcromakalim-Sumatriptan; 20 participants with migraine without aura will receive a 20 min infusion of levcromakalim followed by a 10 min infusion of sumatriptan.	Drug: Levcromakalim; 20 min infusion of 1 mg Levcromakalim followed by either sumatriptan or placebo.; Drug: Sumatriptan; 10 min infusion of 4 mg sumatriptan.
Placebo Comparator: Levcromakalim-Placebo; 20 participants with migraine without aura will receive a 20 min infusion of levcromakalim followed by a 10 min infusion of saline.	Drug: Levcromakalim; 20 min infusion of 1 mg Levcromakalim followed by either sumatriptan or placebo.; Drug: Saline; 10 min infusion of isotonic saline (placebo).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of migraine attacks	A migraine attack is defined as an attack fulfilling either (i) or (ii): (i) Headache fulfilling criteria C and D for migraine without aura according to the International Classification of Headache Disorders 3rd edition: C. Headache has at least two of the following characteristics: unilateral location; pulsating quality; moderate or severe pain intensity (moderate to severe pain intensity is considered ≥4 on the numerical rating scale); aggravation by cough (in-hospital phase) or causing avoidance of routine physical activity (out-hospital phase) D. During headache at least one of the following: nausea and/or vomiting; photophobia and phonophobia (ii) Headache described as mimicking the patient's usual migraine attack and treated with acute migraine medication (rescue medication).	Assessed from baseline to 12 hours after infusion of levcromakalim.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of headache	Incidence of headache is defined as headache intensity ≥1 as measured by a numerical rating scale (NRS) from 0 to 10. It is a verbally declared scale from 0 to 10, where 0 is no pain and 10 is the worst pain imaginable.	Assessed from baseline to 12 hours after infusion of levcromakalim.
Intensity of headache	Headache intensity scores are measured by a numerical rating scale (NRS). It is a verbally declared scale from 0 to 10, where 0 is no pain and 10 is the worst pain imaginable.	Assessed from baseline to 12 hours after infusion of levcromakalim.
Diameter of superficial temporal artery (STA) assessed using high frequency ultrasound	Diameter (mm) of superficial temporal artery (STA) is measured as a continuous outcome using high frequency ultrasound (Dermascan C, Cortex Technology, Denmark).	Assessed from baseline to 2 hours after infusion of levcromakalim.
Incidence of adverse events	Participants are instructed to inform the investigators in the case of adverse events.	Assessed from baseline to 12 hours after infusion of levcromakalim.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of facial flushing	Incidence of facial skin flushing assessed by the investigator as a binary outcome.	Assessed from baseline to 2 hours after infusion of levcromakalim.
Facial blood flow assessed using Laser Doppler Flowmetry	Facial blood flow is measured as a continuous outcome using Laser Doppler Flowmetry (LDI, Moor Instruments, Devon, United Kingdom).	Assessed from baseline to 2 hours after infusion of levcromakalim.

Collaborators and Investigators

• Sponsor: Danish Headache Center
• Investigators: Principal Investigator: Messoud Ashina, Prof., Danish Headache Center

Study record dates

Study Major Dates

• Study Start (Actual): March 15, 2022
• Primary Completion (Actual): November 5, 2023
• Study Completion (Actual): November 5, 2023

Study Registration Dates

• First Submitted: January 4, 2022
• First Submitted That Met QC Criteria: January 26, 2022
• First Posted (Actual): January 27, 2022

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: January 17, 2025
• Last Verified: January 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Headache Disorders, Primary; Headache Disorders; Migraine Disorders; Headache; Migraine without Aura; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Neurotransmitter Agents; Respiratory System Agents; Anti-Asthmatic Agents; Bronchodilator Agents; Vasodilator Agents; Serotonin Agents; Antihypertensive Agents; Vasoconstrictor Agents; Parasympatholytics; Serotonin Receptor Agonists; Serotonin 5-HT1 Receptor Agonists; Sumatriptan; Cromakalim
• Other Study ID Numbers: H-21011542

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No